55.90

2.80% 1.525

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $55.90, with a volume of 948.71K. It is up +2.80% in the last 24 hours and up +5.38% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Previous Close:

$54.37

Open:

$55.12

24h Volume:

948.71K

Relative Volume:

0.61

Market Cap:

$8.56B

Revenue:

$700.35M

Net Income/Loss:

$461.90M

P/E Ratio:

19.48

EPS:

2.8696

Net Cash Flow:

$-14.19M

1W Performance:

+4.79%

1M Performance:

+5.38%

6M Performance:

+61.55%

1Y Performance:

+59.47%

1-Day Range:

$54.76

$56.83

1-Week Range:

$53.36

$55.86

52-Week Range:

$26.76

$59.30

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

399

Twitter

@TGTherapeutics

Next Earnings Date

2026-11-02

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX Tg Therapeutics Inc	55.90	8.56B	700.35M	461.90M	-14.19M	2.8696
VRTX Vertex Pharmaceuticals Inc	509.72	129.19B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.78	94.93B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.11	82.48B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.35	53.35B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.37	42.01B	5.76B	514.49M	1.10B	4.4813

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Resumed	H.C. Wainwright	Buy
Jul-10-25	Resumed	Goldman	Neutral
Oct-29-24	Initiated	TD Cowen	Buy
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

Oct 13, 2026

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Zacks Investment Research

Oct 13, 2026

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - TradingView

Oct 13, 2026

Thermo Fisher to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research

Oct 13, 2026

Oct 12, 2026

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis - BioSpace

Oct 12, 2026

TG Therapeutics (TGTX) Reports Five-Year Study Showing BRIUMVI's - GuruFocus

Oct 12, 2026

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis - Business Wire

Oct 12, 2026

High Growth Tech Stocks To Watch In US October 2026 - Simply Wall Street

Oct 12, 2026

Oct 09, 2026

How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story - Yahoo Finance

Oct 09, 2026

Oct 08, 2026

TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow - Yahoo Finance

Oct 08, 2026

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 - BioSpace

Oct 08, 2026

TG Therapeutics (TGTX) to Present Phase 1 Azer-cel Data and BRIU - GuruFocus

Oct 08, 2026

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 - Business Wire

Oct 08, 2026